Orchid Pharma Ltd
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
- Market Cap ₹ 3,603 Cr.
- Current Price ₹ 710
- High / Low ₹ 1,998 / 604
- Stock P/E 36.2
- Book Value ₹ 250
- Dividend Yield 0.00 %
- ROCE 8.02 %
- ROE 8.18 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 22.5% CAGR over last 5 years
Cons
- Stock is trading at 2.84 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 7.04% over last 3 years.
- Promoter holding has decreased over last 3 years: -20.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 18m | Mar 2015 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,948 | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 922 | |
1,837 | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 805 | |
Operating Profit | 110 | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 117 |
OPM % | 6% | 18% | 20% | 0% | 4% | -2% | -6% | 7% | 10% | 13% | 14% | 13% |
92 | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 27 | |
Interest | 523 | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 15 |
Depreciation | 252 | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 35 |
Profit before tax | -573 | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 96 |
Tax % | -2% | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -0% |
-560 | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 100 | |
EPS in Rs | -79.21 | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -6% |
5 Years: | 14% |
3 Years: | 18% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 23% |
3 Years: | 249% |
TTM: | 8% |
Stock Price CAGR | |
---|---|
10 Years: | 28% |
5 Years: | % |
3 Years: | 30% |
1 Year: | -50% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 7% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 70 | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 |
Reserves | 310 | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,217 |
3,204 | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 175 | |
1,067 | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 | |
Total Liabilities | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
2,584 | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 649 | |
CWIP | 360 | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 64 |
Investments | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 |
1,706 | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 | |
Total Assets | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
168 | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 19 | |
-986 | 1,334 | -1 | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -27 | |
664 | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 25 | |
Net Cash Flow | -153 | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 18 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 34 | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 96 |
Inventory Days | 187 | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 219 |
Days Payable | 220 | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 149 |
Cash Conversion Cycle | -0 | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 166 |
Working Capital Days | -113 | 86 | 97 | -226 | -505 | -735 | 166 | 305 | 136 | 154 | 124 | 152 |
ROCE % | -3% | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 8% |
Documents
Announcements
-
Intimation For Execution Of Deed Of Hypothecation In Favour Of HDFC Bank Limited
17 Jul - Orchid Pharma secures Rs.142.5 Cr loan from HDFC Bank for Cefiderocol Project setup.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jul - Compliance Certificate under Regulation 74(5) of SEBI (Depositories Participants) Regulation, 2018, as amended, for Quarter-I of F.Y. 2025-26 ended on June 30, 2025
-
Intimation Related To The Scheme Of Amalgamation Of Dhanuka
Laboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company/Company') And Their Respective Shareholders And Creditors ('The Scheme') Under Regulation 30 Of SEBI (LODR) Regulations, 2015
10 Jul - Orchid Pharma files Joint Second Motion Petition for amalgamation with Dhanuka Laboratories on July 9, 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
30 Jun - Orchid Pharma shareholders approve amalgamation scheme with Dhanuka Laboratories, over 97% votes in favor.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 Jun - Re-appointment of three independent directors for five years from June 29, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Dec 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
Product Segments FY24
The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]